2-[(4,5-dimethyl-1,3-oxazol-2-yl)methyl]-1-(3-ethoxy-4-methylpentyl)-3-ethylguanidine
C17H32N4O2 — CID 111718218
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-[(4,5-dimethyl-1,3-oxazol-2-yl)methyl]-1-(3-ethoxy-4-methylpentyl)-3-ethylguanidine
2-[(4,5-dimethyl-1,3-oxazol-2-yl)methyl]-1-(3-ethoxy-4-methylpentyl)-3-ethylguanidine (PubChem CID 111718218) has the molecular formula C17H32N4O2 and a molecular weight of 324.47 g/mol. Its IUPAC name is 2-[(4,5-dimethyl-1,3-oxazol-2-yl)methyl]-1-(3-ethoxy-4-methylpentyl)-3-ethylguanidine.
Molecular Properties
| Compound Name | 2-[(4,5-dimethyl-1,3-oxazol-2-yl)methyl]-1-(3-ethoxy-4-methylpentyl)-3-ethylguanidine |
|---|---|
| PubChem CID | 111718218 |
| Molecular Formula | C17H32N4O2 |
| Molecular Weight | 324.47 g/mol |
| Exact Mass | 324.25 |
| IUPAC Name | 2-[(4,5-dimethyl-1,3-oxazol-2-yl)methyl]-1-(3-ethoxy-4-methylpentyl)-3-ethylguanidine |
| SMILES | CCN/C(=N\Cc1nc(C)c(C)o1)NCCC(OCC)C(C)C |
| InChI | InChI=1S/C17H32N4O2/c1-7-18-17(19-10-9-15(12(3)4)22-8-2)20-11-16-21-13(5)14(6)23-16/h12,15H,7-11H2,1-6H3,(H2,18,19,20) |
| InChIKey | YCDCLFCLFNVPBH-UHFFFAOYSA-N |
| XLogP | 2.80 |
| TPSA | 71.68 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 9 |
| Heavy Atoms | 23 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 324.47 |
| LogP ≤ 5 | 2.80 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'imine_1', 'substructure': 'N/A'}, {'alert_name': 'imine_2', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 111718218 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.